ARCHIVES

PD-1 Checkpoint Inhibitor Opdivo First to Demonstrate Survival Benefit in Phase III

This article is from The Cancer Letter archive.

Vol. 37 No. 11 | November 28, 2014

Download PDF Visit The Full Archive

Related Articles

In Brief: NCAB To Ponder Organ Systems Program Fate, Cancer Centers Issues, Hear Surveillance Review

January 29, 1988

Regulatory Agencies: Health Warnings Sought on Cigars

July 23, 1999

Obey Again – Now He’s Blasting NCI For Not Helping NIOSH

September 17, 1976

Guest Editorial: Group Chairs Urge Implementation of NCI plan. Next Step: Bioinformatics and Tissue Banks

November 11, 2011

Two-Point Rise In PSA Signals High-Risk Prostate Cancer

August 26, 2005

More Cost-Effective To Use Cetuximab In Patients With Wild-Type KRAS Gene

August 28, 2009